Acute Coronary Syndrome
Conditions
Keywords
Acute Coronary Syndrome, Mobile Health, Secondary Prevention
Brief summary
HARKIT I-Care is a mobile application developed by the National Cardiovascular Center Harapan Kita (NCCHK) to leverage patients in achieving their targets for the secondary prevention of cardiovascular diseases. The application contains various features, including exercise tracking and reminder, medication reminder, and updated educational content on cardiovascular health. Additionally, patients can log and record their blood pressure, heart rate, smoking behavior, Quality of Life, and laboratory parameters such as blood sugar and cholesterol. Our research aims to investigate whether implementing this app in post-acute coronary syndrome patients could improve their survival rate, hospitalization rate, medication adherence, and Quality of Life, along with improving their laboratory parameters to be within desirable targets.
Detailed description
Design: This study is a single-blinded, randomized clinical trial conducted in the National Cardiovascular Center Harapan Kita, and aims to investigate the effect of the mobile application HARKIT I-Care on the morbidity and mortality of post-acute coronary syndrome patients. Subjects: Post-ACS patients hospitalized at the National Cardiovascular Center who are willing to be a subject in this research and have signed the informed consent form. Eligible subjects will be recruited and randomized to two groups: I-Care and control. Subjects in the I-Care group will be instructed to download 'HARKIT I-Care' application on their smartphone. Subjects will then be taught how to use the application, including logging blood pressure, blood sugar, and cholesterol levels, making use of exercise and medication reminders, and where to access health information and teleconsultation. Subjects are instructed to log their health parameters regularly according to the guidebook that has been prepared beforehand. Subjects in the control group will receive education on medication compliance and health information at the beginning of the enrolment. Education was conducted by another research team not involved in assessing outcomes. Randomization: We conducted stratified permutated block random sampling using a computer application. Stratification used were: (1) Gender: male and female, (2) Age: \<65 and ≥65, and (3) Diagnosis: STEMI (ST-Elevation Myocardial Infarction), NSTEMI (Non-ST-segment Elevation Myocardial Infarction), and UAP (Unstable Angina Pectoris). Randomization was conducted using a computer app, and patient assignments were done using a sealed opaque envelope containing the assignment group. Randomization was conducted by a study statistician not involved in data collection. Outcome assessors were blinded to the treatment. Statistical Analysis plan: We planned on conducting a survival analysis for MACE (major adverse cardiovascular events), cardiovascular mortality, all-cause mortality, and rehospitalization rate. We also intended to analyze the effect of HARKIT I-Care on medication compliance, laboratory parameters, smoking cessation and relapse, sodium consumption, and physical activity.
Interventions
DEVICEHARKIT I-Care Application
HARKIT I-Care Application is an application available in the google play store. The application is specifically developed for the secondary prevention of cardiovascular disease. The features included in the application are (1) Health information logging, (2) Health information education, and (3) Teleconsultation with a cardiologist. Information that can be logged includes smoking behavior, medications, weight, blood sugar level, blood pressure, cholesterol level, physical activity, and Quality of life. Educational content can be accessed by patients in the form of articles and short videos.
Sponsors
National Cardiovascular Center Harapan Kita Hospital Indonesia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Caregiver, Outcomes Assessor)
Intervention model description
This study is a single-blind, randomized, controlled clinical trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Acute Coronary Syndrome (ACS) patients, either ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), or unstable angina pectoris (UAP) who have or have not undergone revascularization treatment
Exclusion criteria
* Does not have or know how to operate smartphone * Unable to perform a smartphone due to hearing, vision, or cognitive impairment * Withdrawn consent from the research
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rehospitalization | 6 months | Rehospitalization is defined as all unplanned visits to the hospital, both to the emergency department or inpatient ward, with the diagnosis of cardiovascular diseases and related complications (bleeding, hypertension crisis, and hyperglycemia crisis). Events of the planned visit to the hospital are excluded. |
| All-Cause Mortality | 6 months | All deaths, both cardiovascular mortality and non-cardiovascular mortality |
| Cardiovascular Mortality | 6 months | We defined Cardiovascular Mortality as all deaths, excluding deaths which etiology definitely was a non-cardiovascular etiology |
| Major Adverse Cardiovascular Event | 6 months | Major Adverse Cardiovascular Event (MACE) is described as all cardiovascular deaths, myocardial infarction, stroke, heart failure hospitalization, and revascularization event |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total Cholesterol Level (mg/dL) | 1, 3, and 6 months | Total Cholesterol level (in mg/dL) is measured at NCCHK laboratory |
| HDL Level (mg/dL) | 1, 3, and 6 months | HDL level (in mg/dL) is measured at NCCHK laboratory |
| LDL Level (mg/dL) | 1, 3, and 6 months | LDL level (in mg/dL) is measured at NCCHK laboratory |
| Triglyceride Level (mg/dL) | 1, 3, and 6 months | Triglyceride level (in mg/dL) is measured at NCCHK laboratory |
| Blood Glucose Level (mg/dL) | 1, 3, and 6 months | Blood Glucose Level (in mg/dL) is measured at NCCHK laboratory, including fasting blood glucose and postprandial blood glucose |
| HbA1c (%) | 1, 3, and 6 months | HbA1c (in %) is measured at NCCHK laboratory |
| Physical activity level | 1, 3, and 6 months | Physical activity level is measured using the International Physical Activity Questionnaire (IPAQ). The result of the questionnaire will be converted into MET minutes |
| Medication Adherence | 1, 3, and 6 months | Medication adherence is measured using Morisky Medication Adherence Scale (MMAS)-8 questionnaire. The questionnaire contained 8 items, and each subject scored 1-8. Interpretation of the questionnaire is as follows: 8=high adherence, 7=medium adherence, ≤6=low adherence |
| Heart Disease Fact Questionnaire (HDFQ) | 1, 3, and 6 months | HDFQ is a questionnaire measuring patient's knowledge regarding coronary heart disease risk factor |
| Indirect Cost | 1, 3, and 6 months | Indirect cost is defined as the cost used for transportation, consumption, accommodation, and caregiver hiring purposes. The data is gathered from direct interviews with subjects using the standardized instrument that had been prepared. The components are transportation, consumption, medical devices purchase, house renovation to foster medical necessities, caregiver fees, and loss of opportunity cost (the wage that should have been received if the subject works) |
| Quality-adjusted Life Years (QALYs) | 1, 3, and 6 months | QALYs are defined as the measure of health outcomes used to discover the effect of the intervention toward cost-effective analysis. This measurement is calculated by estimating the years of life remaining for a patient following a particular treatment or intervention multiplied by the changes in health quality caused by the intervention using the EQ-5D-5L questionnaire. |
| Cost-Utility Analysis | 1, 3, and 6 months | Cost-utility analysis is defined as incremental cost-effectiveness ratio (ICER), which is the absolute value calculated from the differences in cost between intervention and control divided by the differences of outcomes yielded. |
| Direct Cost | 1, 3, and 6 months | Direct cost is defined as the cost for outpatient clinic visits, medications, supporting examinations, and interventional procedures (including percutaneous coronary intervention and coronary artery bypass graft). It is measured from data stored in the finance department and information system of the hospital. |
| SF-36 Quality of Life Questionnaire | 1, 3, and 6 months | SF 36 is a questionnaire developed to assess the Quality of Life in patients. Each question is scored from 0-100 and transformed into different scales (Physical functioning, Role limitations due to physical health, Role limitations due to emotional problems, Energy/fatigue, emotional well-being, social functioning, pain, and general health). |
| Sodium Consumption | 1, 3, and 6 months | Sodium consumption is measured using WHO STEPS questionnaire |
| Smoking Cessation | 6 months | Smoking cessation is defined as the number of patients who at the time of recruitment are active smokers and at the time of final follow up the patients have stopped smoking for at least one month |
| Smoking Relapse | 6 months | Smoking relapse is defined as patient who at the time of recruitment is an ex smoker (defined as at least 1 month smoke-free before the time of recruitment) but during follow up time picks up smoking again |
Other
| Measure | Time frame | Description |
|---|---|---|
| Application Uptake | 1, 3, and 6 months | Application uptake is defined as at least one day of health data logged by subject in HARKIT I-Care application |
| Application Completion | 1, 3, and 6 months | Application Completion is defined as the number of subjects who use the application for at least 6 months and recorded at the final follow-up period |
| Application Adherence | 1, 3, and 6 months | Application Adherence is defined as the number of patients who use the application based on the guideline provided for them for at least 12 days per month of health data logged by subject in HARKIT I-Care |
Countries
Indonesia
Contacts
Primary ContactBambang Dwiputra, MD
Outcome results
None listed